• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CARDIOVASCULAR SYSTEMS CORPORATION STERILE FX25RWC W/ RES; BLOOD GAS OXYGENATOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CARDIOVASCULAR SYSTEMS CORPORATION STERILE FX25RWC W/ RES; BLOOD GAS OXYGENATOR Back to Search Results
Model Number 3CX*FX25RWC
Device Problem Device Markings/Labelling Problem (2911)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 09/04/2023
Event Type  malfunction  
Manufacturer Narrative
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.  h6: component code: 4739 - gas exchanger.Health effect - impact code: 2645 - no patient involvement.Health effect - clinical code: 4582 - no clinical, signs, symptoms or conditions.Medical device problem code: 2911 - device markings / labelling problem.Investigation findings: 3233 - results pending completion of investigation.Investigation conclusions: 11 - conclusion not yet available.
 
Event Description
The user facility reported to terumo cardiovascular that during other - non clinical activity, the label details on the oxygenator were incomplete.As per the subsidiary, the defect was observed during incoming receipt, and it was not used in any product assembled.A single oxygenator was found within a larger shipment, for which the oxygenator label details were incomplete, missing information pertaining to the lot and use by date.No patient involvement.
 
Manufacturer Narrative
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on september 20, 2023.Upon further investigation of the reported event, the following information is new and/or changed: d4 (updated lot number); d9 (device availability - added date returned to manufacturer); g3 (date received by manufacturer) ; g6 (indication that this is a follow-up report) ; h2 (follow-up due to additional information) ; h3 (device evaluation anticipated by manufacturer - a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
 
Event Description
The oxygenator label details were incomplete.
 
Event Description
The oxygenator label details were incomplete.
 
Manufacturer Narrative
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added expiration date).G3 (date received by manufacturer).G6 (indication that this is a follow-up report).H2 (follow-up due to additional information and device evaluation).H3 (device evaluated by manufacturer).H4 (device manufacture date).H6 (identification of evaluation codes 10, 11, 3331, 154, 25).Type of investigation #1: 10 - testing of actual/suspected device.Type of investigation #2: 11 - testing of device from same lot/batch retained by manufacturer.Type of investigation #3: 3331 - analysis of production records.Investigation findings: 154 - inadequate labelling and/or instructions for use.Investigation conclusions: 25 - cause traced to manufacturing.The returned sample was inspected upon receipt and confirmed that the lot number and expiration date information were missing from the product label on the reservoir.A representative retention sample from the same lot number was inspected and confirmed to have all the required information on the product label.All capiox products are 100% visually inspected during the manufacturing and packaging process.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
STERILE FX25RWC W/ RES
Type of Device
BLOOD GAS OXYGENATOR
Manufacturer (Section D)
TERUMO CARDIOVASCULAR SYSTEMS CORPORATION
125 blue ball road
elkton MD 21921
Manufacturer (Section G)
SAME
Manufacturer Contact
douglas patton
125 blue ball road
elkton, MD 21921
7346634145
MDR Report Key17783400
MDR Text Key323863074
Report Number1124841-2023-00229
Device Sequence Number1
Product Code DTZ
Combination Product (y/n)N
Reporter Country CodeUK
PMA/PMN Number
K151791
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,User Facility,Company Representative
Reporter Occupation Non-Healthcare Professional
Type of Report Initial,Followup,Followup
Report Date 11/02/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/20/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Other
Device Model Number3CX*FX25RWC
Device Catalogue NumberN/A
Device Lot Number3E10
Was Device Available for Evaluation? Device Returned to Manufacturer
Was the Report Sent to FDA? No
Date Manufacturer Received10/30/2023
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured04/10/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-